BC Week In Review | Jul 11, 2016
Company News

Uni-Bio Science Group, China Resources Pharmaceutical deal

Uni-Bio granted exclusive, Chinese commercialization rights to GeneSoft to the China Resources Zizhu Pharmaceutical Co. Ltd. subsidiary of China Resources Pharmaceutical. Zizhu will have rights to GeneSoft for five years, with an option to renew...
BC Extra | Jun 28, 2016
Company News

Zizhu gets China rights to Uni-Bio's eye drug

Uni-Bio Science Group Ltd. (HKSE:690) said it granted exclusive commercialization rights in China to ophthalmology treatment GeneSoft to the China Resources Zizhu Pharmaceutical Co. Ltd. subsidiary of China Resource Pharmaceuticals Group (Beijing, China). Zizhu will...
BioCentury | Feb 8, 2010
Strategy

Out from Down Under

A dearth of funding often forces Australian companies to out-license products too early in development to get any meaningful revenues out of them, because they can't afford to get them to market by themselves. By...
BioCentury | Sep 18, 2006
Product Development

FDA's superior attitude

An application by Oscient Pharmaceuticals Corp. to market Factive gemifloxacin for the treatment of acute bacterial sinusitis has become the battleground for a long-simmering debate within FDA and the infectious disease community about the acceptability...
BioCentury | May 2, 2005
Finance

Going big

Going big Company Date Offering Raised (M) Eyetech (EYET) 8/7/01 Series C $108.5 Biovitrum (A)(B) 8/1/01 Series A $85.0 Perlegen (B) 2/28/05 Series D $74.0 Genesoft (A)(C) 6/30/02 ND $70.0 Corus 4/12/04 Series C $65.0...
BioCentury | Jul 26, 2004
Strategy

RAVE goodbye and move on

After four years of sluggish enrollment in its RAVE Phase III trial of Ramoplanin to prevent vancomycin-resistant enterococci (VRE), Oscient Pharmaceuticals Inc. has decided to move on to more fertile fields. It will focus instead...
BioCentury | May 10, 2004
Finance

Ebb & Flow

ImClone (IMCL) boosted its war chest by half a billion dollars last week, thanks to a bumped-up convertible note deal. What's more, the company does not expect that it will have to earmark the proceeds...
BC Extra | May 5, 2004
Financial News

Oscient raises $125 million

GENE raised $125 million in a bumped-up private placement of convertible notes. The notes bear 3.5% interest, mature on April 15, 2011, and convert into GENE stock at $6.64 per share, a 35% premium to...
BC Extra | May 3, 2004
Financial News

Oscient proposes $75 million note deal

Oscient (formerly Genome Therapeutics ) proposed to raise about $75 million through the sale of senior convertible notes. The notes will mature in 2011 and convert into stock at a to-be-determined price. The deal has a...
BC Extra | Apr 13, 2004
Company News

GENE changes name to Oscient

Genome Therapeutics (GENE) changed its name to Oscient , a move that follows GENE's February merger with Genesoft . The stock will continue to trade under the symbol GENE. The company said the name change reflects its...
Items per page:
1 - 10 of 48
BC Week In Review | Jul 11, 2016
Company News

Uni-Bio Science Group, China Resources Pharmaceutical deal

Uni-Bio granted exclusive, Chinese commercialization rights to GeneSoft to the China Resources Zizhu Pharmaceutical Co. Ltd. subsidiary of China Resources Pharmaceutical. Zizhu will have rights to GeneSoft for five years, with an option to renew...
BC Extra | Jun 28, 2016
Company News

Zizhu gets China rights to Uni-Bio's eye drug

Uni-Bio Science Group Ltd. (HKSE:690) said it granted exclusive commercialization rights in China to ophthalmology treatment GeneSoft to the China Resources Zizhu Pharmaceutical Co. Ltd. subsidiary of China Resource Pharmaceuticals Group (Beijing, China). Zizhu will...
BioCentury | Feb 8, 2010
Strategy

Out from Down Under

A dearth of funding often forces Australian companies to out-license products too early in development to get any meaningful revenues out of them, because they can't afford to get them to market by themselves. By...
BioCentury | Sep 18, 2006
Product Development

FDA's superior attitude

An application by Oscient Pharmaceuticals Corp. to market Factive gemifloxacin for the treatment of acute bacterial sinusitis has become the battleground for a long-simmering debate within FDA and the infectious disease community about the acceptability...
BioCentury | May 2, 2005
Finance

Going big

Going big Company Date Offering Raised (M) Eyetech (EYET) 8/7/01 Series C $108.5 Biovitrum (A)(B) 8/1/01 Series A $85.0 Perlegen (B) 2/28/05 Series D $74.0 Genesoft (A)(C) 6/30/02 ND $70.0 Corus 4/12/04 Series C $65.0...
BioCentury | Jul 26, 2004
Strategy

RAVE goodbye and move on

After four years of sluggish enrollment in its RAVE Phase III trial of Ramoplanin to prevent vancomycin-resistant enterococci (VRE), Oscient Pharmaceuticals Inc. has decided to move on to more fertile fields. It will focus instead...
BioCentury | May 10, 2004
Finance

Ebb & Flow

ImClone (IMCL) boosted its war chest by half a billion dollars last week, thanks to a bumped-up convertible note deal. What's more, the company does not expect that it will have to earmark the proceeds...
BC Extra | May 5, 2004
Financial News

Oscient raises $125 million

GENE raised $125 million in a bumped-up private placement of convertible notes. The notes bear 3.5% interest, mature on April 15, 2011, and convert into GENE stock at $6.64 per share, a 35% premium to...
BC Extra | May 3, 2004
Financial News

Oscient proposes $75 million note deal

Oscient (formerly Genome Therapeutics ) proposed to raise about $75 million through the sale of senior convertible notes. The notes will mature in 2011 and convert into stock at a to-be-determined price. The deal has a...
BC Extra | Apr 13, 2004
Company News

GENE changes name to Oscient

Genome Therapeutics (GENE) changed its name to Oscient , a move that follows GENE's February merger with Genesoft . The stock will continue to trade under the symbol GENE. The company said the name change reflects its...
Items per page:
1 - 10 of 48